Last updated: 2026-11-14 20:08:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Nektar Therapeutics (NKTR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $37.30, with a market capitalization of $1.27B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $33.40 to $109.00. This page covers its latest market performance, valuation, price trends and company information.
$1.27B | |
$36.80 | |
$38.77 | |
$36.47 | |
$37.25 | |
601.58K | |
1.11M | |
-- | |
$109.00 | |
$33.40 | |
-- | |
-- |
Nektar Therapeutics (NKTR) last closed at $37.30 as of 2026-11-14 00:31:00, up 0.19% ($0.07) from the previous close of $37.25.
During the latest regular trading session, NKTR traded between $36.47 and $38.77, with a volume of 601.58K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Nektar Therapeutics (NKTR) moved from $36.15 to $37.30, representing a gain of 3.17% ($1.15).
The stock traded between $35.76 and $39.10 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 644.32 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5.2%
NKTR is currently trading at $37.30, placing it 5.2% of the way from its 52-week low of $33.40 to its 52-week high of $109.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 63 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Nektar Therapeutics and NKTR stock.
Nektar Therapeutics reported a quarterly loss of $1.63 per share, beating the consensus estimate of $2.16 loss by 24.54%, but missed revenue expectations with $9.39 million versus the estimated $10.23 million. The stock has underperformed the S&P 500 by 20.4% year-to-date. Despite the revenue miss, Nektar holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.63) per share which beat the analyst consensus estimate of $(2.08) by 21.63 percent. This is a 12.83 percent increase over losses of $(1.87) per share
Eligible investors can buy real shares of Nektar Therapeutics (NKTR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NKTR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NKTR shares and USD.
NKTR Shares to USD
1.00 NKTR shares = 37.296 USD
Calculations are estimates based on the latest available price and are for reference only.
